Statin therapy associated with decreased neuronal injury measured by serum S100β levels in patients with acute ischemic stroke

Abstract

Background: Acute ischemic strokes (AIS) are a common cause of morbidity, mortality, and disability. The serum biomarker S100β correlates with poor neurological outcomes in the setting of AIS. This study describes the impact of statin treatment on S100β levels following AIS. Methods: This was a prospective case–control study of AIS patients compared to healthy controls. Patients were stratified into three groups: (1) AIS patients on statin therapy, (2) AIS patients not on statin therapy, and (3) healthy controls. Demographics, clinical parameters, stroke risk scores (SRS), and S100β levels were recorded for all patients. Results: Blood pressure, lipids, and SRS scores were higher in stroke versus control patients (all P < 0.05), and lower in Group I versus II (all P < 0.05). S100β levels were higher in stroke versus nonstroke patients ( P = 0.001), and lower in Group I versus II ( P = 0.001). Furthermore, patients on atorvastatin showed greater S100β reductions than those on rosuvastatin therapy ( P = 0.01). Conclusion: In acute stroke patients, statins therapy correlated with reductions in the neuronal injury biomarker S100β, with greater reductions observed for atorvastatin than rosuvastatin therapy.

Efficacy of Rosuvastatin Combined with rt-PA Intravenous Thrombolytic Therapy for Elderly Acute Ischemic Stroke Patients

“…First, the overall efficacy was statistically higher in the observation group when compared to the control group. Al-Kuraishy et al [ 24 ] pointed out in their study that the application of ROS in AIS patients has certain efficacy, which can improve the cardiac metabolism of patients and lower the risk of stroke recurrence. Lu et al [ 25 ] also confirmed the effectiveness of ROS in AIS in animal experiments, mainly reflected in the prevention of blood-brain barrier damage.…”

Pros and cons for statins use and risk of Parkinson's disease: An updated perspective

“… 24 Hydrophilic statins are less cross‐plasma membrane so they have less pleiotropic effects compared to lipophilic statins. 24 Of note, statins are also classified according to their nature, either natural like simvastatin and lovastatin, or synthetic like rosuvastatin. 24 Natural and synthetic statins have different pharmacokinetic properties but they have similar lipid‐lowering effects.…”

“… 24 Of note, statins are also classified according to their nature, either natural like simvastatin and lovastatin, or synthetic like rosuvastatin. 24 Natural and synthetic statins have different pharmacokinetic properties but they have similar lipid‐lowering effects. Remarkably, statins lead to a dose‐dependent effect in reducing cholesterol and LDL.…”

“…Prolonged use of statins is associated with the development of various adverse effects including muscle pain, increase risk of diabetes mellitus, and some cognitive dysfunction 23 . There are two types of statins either lipophilic like atorvastatin and simvastatin or hydrophilic like rosuvastatin 24 . Hydrophilic statins are less cross‐plasma membrane so they have less pleiotropic effects compared to lipophilic statins 24 .…”

“…There are two types of statins either lipophilic like atorvastatin and simvastatin or hydrophilic like rosuvastatin 24 . Hydrophilic statins are less cross‐plasma membrane so they have less pleiotropic effects compared to lipophilic statins 24 . Of note, statins are also classified according to their nature, either natural like simvastatin and lovastatin, or synthetic like rosuvastatin 24 .…”